PURPOSE: Heat shock protein 90 (Hsp90), a potential therapeutic target, has been widely recognized in vitro and in vivo in immunodeficient mice. Here, we aimed to evaluate the role of Hsp90 in an immunocompetent mouse model of esophageal squamous cell cancer (ESCC). METHODS: The carcinogen 4-nitroquinoline 1-oxide (4NQO) was used to induce ESCC in C57BL/6 mice. Cancer progression was analyzed through observation of appearance, hematoxylin-eosin staining, immunohistochemical detection, and terminal dUTP nick-end labeling analysis. RESULTS: 4NQO led to the progressive appearance of preneoplastic and tumoral lesions in the esophagus, with 100 % incidence of ESCC in situ occurring only after 16 weeks of carcinogen exposure. Most of these lesions evolved spontaneously into highly invasive ESCC even after 4NQO withdrawal (weeks 16-22). Interestingly, there was marked upregulation of Hsp90 and its client proteins in tumoral lesions at 22 weeks. Hsp90 inhibition by intraperitoneal injection of SNX-2112 over the following 2 weeks downregulated AKT and cyclin D1 expression, leading to significant reduction in tumor incidence and prevention of ESCC progression. Moreover, SNX-2112 treatment decreased proliferating cell nuclear antigen expression and increased the number of apoptotic cells in ESCC tissues. CONCLUSIONS: Our in vivo findings support the contribution of Hsp90 to ESCC progression, which was achieved by stimulating apoptosis and inhibition of cell proliferation, and provide a strong rationale for further evaluation of Hsp90 inhibitors for treating ESCC.
PURPOSE:Heat shock protein 90 (Hsp90), a potential therapeutic target, has been widely recognized in vitro and in vivo in immunodeficientmice. Here, we aimed to evaluate the role of Hsp90 in an immunocompetent mouse model of esophageal squamous cell cancer (ESCC). METHODS: The carcinogen 4-nitroquinoline 1-oxide (4NQO) was used to induce ESCC in C57BL/6 mice. Cancer progression was analyzed through observation of appearance, hematoxylin-eosin staining, immunohistochemical detection, and terminal dUTP nick-end labeling analysis. RESULTS:4NQO led to the progressive appearance of preneoplastic and tumoral lesions in the esophagus, with 100 % incidence of ESCC in situ occurring only after 16 weeks of carcinogen exposure. Most of these lesions evolved spontaneously into highly invasive ESCC even after 4NQO withdrawal (weeks 16-22). Interestingly, there was marked upregulation of Hsp90 and its client proteins in tumoral lesions at 22 weeks. Hsp90 inhibition by intraperitoneal injection of SNX-2112 over the following 2 weeks downregulated AKT and cyclin D1 expression, leading to significant reduction in tumor incidence and prevention of ESCC progression. Moreover, SNX-2112 treatment decreased proliferating cell nuclear antigen expression and increased the number of apoptotic cells in ESCC tissues. CONCLUSIONS: Our in vivo findings support the contribution of Hsp90 to ESCC progression, which was achieved by stimulating apoptosis and inhibition of cell proliferation, and provide a strong rationale for further evaluation of Hsp90 inhibitors for treating ESCC.
Authors: Marco A Biamonte; Ryan Van de Water; Joseph W Arndt; Robert H Scannevin; Daniel Perret; Wen-Cherng Lee Journal: J Med Chem Date: 2010-01-14 Impact factor: 7.446
Authors: J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: Kenneth H Huang; James M Veal; R Patrick Fadden; John W Rice; Jeron Eaves; Jon-Paul Strachan; Amy F Barabasz; Briana E Foley; Thomas E Barta; Wei Ma; Melanie A Silinski; Mei Hu; Jeffrey M Partridge; Anisa Scott; Laura G DuBois; Tiffany Freed; Paul M Steed; Andy J Ommen; Emilie D Smith; Philip F Hughes; Angela R Woodward; Gunnar J Hanson; W Stephen McCall; Christopher J Markworth; Lindsay Hinkley; Matthew Jenks; Lifeng Geng; Meredith Lewis; James Otto; Bert Pronk; Katleen Verleysen; Steven E Hall Journal: J Med Chem Date: 2009-07-23 Impact factor: 7.446
Authors: Christoph Steurer; Sarah Kerschbaum; Christina Wegrostek; Stefan Gabriel; Ali Hallaj; Viktoria Ortner; Thomas Czerny; Elisabeth Riegel Journal: Mol Biotechnol Date: 2022-02-26 Impact factor: 2.860
Authors: Helga Weber; José R Valbuena; Mustafa A Barbhuiya; Stefan Stein; Hana Kunkel; Patricia García; Carolina Bizama; Ismael Riquelme; Jaime A Espinoza; Stephen E Kurtz; Jeffrey W Tyner; Juan Francisco Calderon; Alejandro H Corvalán; Manuel Grez; Akhilesh Pandey; Pamela Leal-Rojas; Juan C Roa Journal: Oncotarget Date: 2017-04-18